Probiotics for better anemia treatment in kidney disease
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether taking probiotics (beneficial bacteria) can help make your erythropoietin medicine work better for treating anemia related to kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have end-stage kidney disease (your kidneys are working at less than 15% of normal).
- You have been on regular dialysis (a machine that cleans your blood) for at least 3 months.
- You are currently taking a steady dose of erythropoietin (a medicine to help your body make red blood cells).
- You are willing and able to give written permission (informed consent) to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
This study tests whether taking probiotics (good bacteria) or synbiotics (probiotics plus fiber) can improve the nutritional health of people on dialysis. It may help those who struggle with nutrition while waiting for a kidney transplant.
This study looks at how well erythropoietin (a drug that helps your body make red blood cells) works for people with end-stage kidney disease who are on regular hemodialysis. It also checks if metabolic syndrome (a group of conditions like high blood sugar, high blood pressure, and extra belly fat) affects how well this drug works.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This study is testing a new way to manage anemia (low red blood cells) in people on long-term dialysis. It aims to improve how doctors treat this common issue.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.